Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At ...

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.

The stock's fall snapped a three-day winning streak.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

U.S. approves conditional use of avian influenza vaccine amid spreading outbreak U.S. greenlights temporary use of bird flu ...

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day. In the most recent trading session, Novavax (NVAX) closed at $8.45, ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.